ClinicalTrials.Veeva

Menu

Ventricular Reversed Remodeling After LTX in PAH Patients (PAH-LTX)

U

University Medical Center Groningen (UMCG)

Status

Completed

Conditions

Pulmonary Arterial Hypertension

Study type

Observational

Funder types

Other

Identifiers

NCT02391441
METc2014/134

Details and patient eligibility

About

The investigators will evaluate ventricular reversed remodelling after double lung transplantation (LTX) in patients with pulmonary arterial hypertension (PAH), measured with cardiac magnetic resonance imaging (MRI). Reversed remodelling will be compared with control patients without PAH (e.g. Cystic Fibrosis) who will also undergo LTX.

Full description

In this study, pre-LTX and six-months post-LTX measurements will be compared with each other and between the primary and control group.

Pre- and post-LTX measurements include:

Past medical history: Including basic diagnosis; interventions, surgery and transplant related complications (re-operations, hospitalizations, infections) and medication history; These data will be collected by studying the medical files including surgical reports.

Present medical history: Including NYHA class.

Physical examination: Including length and weight.

Cardiac Magnetic Resonance Imaging:

  • Ventricular volume, function and mass measurements
  • Flow measurements of the pulmonary artery and aorta
  • Disease specific measurements (e.g. septal bowing, RV trabecularisation, etc.)
  • T1-mapping

Transthoracic Echocardiography

Resting ECG: Disease specific electrophysiological findings (e.g. QRS-duration, right bundle branch block).

Laboratory evaluation:

  • NT-pro-BNP
  • eGFR
  • Remaining serum will be stored.

Enrollment

17 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients who are on the waiting list for double-LTX, in our institution, for pulmonary arterial hypertension.
  • Eligible for CMR imaging
  • No claustrophobia
  • No pacemaker, ICD, etc.
  • Informed consent

Exclusion criteria

  • Inability to comply with primary endpoint measures.
  • Body mass index ≥40 kg/m2.
  • Pregnant patients will not be included, they may be included >3 months after pregnancy.
  • Patients with age <18 years.

Trial design

17 participants in 2 patient groups

Pulmonary arterial hypertension
Description:
Patients who are on the waiting list for double-LTX for pulmonary arterial hypertension.
Control group
Description:
Control patients without increased pulmonary artery pressure (i.e. RV peak pressure \<35 mmHg measured with echocardiography) who are on the waiting list for double-LTX.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems